Sana Biotechnology, Inc. Research and Development Expense
Sana Biotechnology, Inc. (SANA) reported Research and Development Expense of $30.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Sana Biotechnology, Inc. research and development expense for the quarter ending 2026-06-30 was $30.73M, a 3.25% increase year-over-year.
- Sana Biotechnology, Inc. research and development expense for the quarter ending 2026-03-31 was $28.72M, a 22.78% decline year-over-year.
- Sana Biotechnology, Inc. research and development expense for the quarter ending 2025-12-31 was $34.92M, a 22.64% decline year-over-year.
- Sana Biotechnology, Inc. research and development expense for the quarter ending 2025-09-30 was $30.11M, a 43.42% decline year-over-year.
- Sana Biotechnology, Inc. research and development expense for fiscal 2025 was $131.98M, a 38.81% decline from fiscal 2024.
- Sana Biotechnology, Inc. research and development expense for fiscal 2024 was $215.67M, a 17.62% decline from fiscal 2023.
- Sana Biotechnology, Inc. research and development expense for fiscal 2023 was $261.81M, a 8.42% decline from fiscal 2022.
- Sana Biotechnology, Inc. research and development expense for fiscal 2022 was $285.88M, a 14.99% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $30.73M 10-Q · filed 2026-08-10 | $59.45M 10-Q · filed 2026-08-10 | $94.37M derived: sum of 3 quarters · filed 2026-08-10 | $124.48M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $28.72M 10-Q · filed 2026-05-11 | $63.64M derived: sum of 2 quarters · filed 2026-05-11 | $93.75M derived: sum of 3 quarters · filed 2026-05-11 | $123.51M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $34.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $65.03M derived: sum of 2 quarters · filed 2026-03-03 | $94.79M derived: sum of 3 quarters · filed 2026-08-10 | $131.98M 10-K · filed 2026-03-03 | ||
| 2025-09-30 | $30.11M 10-Q · filed 2025-11-06 | $59.87M derived: sum of 2 quarters · filed 2026-08-10 | $97.06M 10-Q · filed 2025-11-06 | $142.20M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $29.76M 10-Q · filed 2026-08-10 | $66.95M 10-Q · filed 2026-08-10 | $112.09M derived: sum of 3 quarters · filed 2026-08-10 | $165.30M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $37.19M 10-Q · filed 2026-05-11 | $82.33M derived: sum of 2 quarters · filed 2026-05-11 | $135.54M derived: sum of 3 quarters · filed 2026-05-11 | $196.41M derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $45.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $98.35M derived: sum of 2 quarters · filed 2026-03-03 | $159.22M derived: sum of 3 quarters · filed 2026-03-03 | $215.67M 10-K · filed 2026-03-03 | $217.56M 10-K · filed 2025-03-17 | |
| 2024-09-30 | $53.21M 10-Q · filed 2025-11-06 | $114.08M derived: sum of 2 quarters · filed 2025-11-06 | $170.53M 10-Q · filed 2025-11-06 | $226.51M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $60.87M 10-Q · filed 2025-08-11 | $117.32M 10-Q · filed 2025-08-11 | $173.31M derived: sum of 3 quarters · filed 2026-03-03 | $238.92M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $56.45M 10-Q · filed 2025-05-08 | $112.43M derived: sum of 2 quarters · filed 2026-03-03 | $178.05M derived: sum of 3 quarters · filed 2026-03-03 | $251.09M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | $55.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $121.60M derived: sum of 2 quarters · filed 2026-03-03 | $194.64M derived: sum of 3 quarters · filed 2026-03-03 | $261.81M 10-K · filed 2026-03-03 | $268.82M 10-K · filed 2024-02-29 | |
| 2023-09-30 | $65.61M 10-Q · filed 2024-11-08 | $138.66M derived: sum of 2 quarters · filed 2024-11-08 | $205.82M 10-Q · filed 2024-11-08 | $269.74M derived: sum of 4 quarters · filed 2025-03-17 | ||
| 2023-06-30 | $73.04M 10-Q · filed 2024-08-08 | $140.21M 10-Q · filed 2024-08-08 | $204.13M derived: sum of 3 quarters · filed 2025-03-17 | $280.87M derived: sum of 4 quarters · filed 2025-03-17 | ||
| 2023-03-31 | $67.17M 10-Q · filed 2024-05-08 | $131.09M derived: sum of 2 quarters · filed 2025-03-17 | $207.82M derived: sum of 3 quarters · filed 2025-03-17 | $280.36M derived: sum of 4 quarters · filed 2025-03-17 | ||
| 2022-12-31 | $63.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $140.66M derived: sum of 2 quarters · filed 2025-03-17 | $213.20M derived: sum of 3 quarters · filed 2025-03-17 | $285.88M 10-K · filed 2025-03-17 | ||
| 2022-09-30 | $76.73M 10-Q · filed 2023-11-08 | $149.28M derived: sum of 2 quarters · filed 2023-11-08 | $221.96M 10-Q · filed 2023-11-08 | $330.47M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | $72.54M 10-Q · filed 2023-08-03 | $145.23M 10-Q · filed 2023-08-03 | $253.73M derived: sum of 3 quarters · filed 2024-02-29 | $306.98M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-03-31 | $72.69M 10-Q · filed 2023-05-08 | $181.19M derived: sum of 2 quarters · filed 2024-02-29 | $234.44M derived: sum of 3 quarters · filed 2024-02-29 | $279.44M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $108.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $161.75M derived: sum of 2 quarters · filed 2024-02-29 | $206.75M derived: sum of 3 quarters · filed 2024-02-29 | $248.63M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $53.24M 10-Q · filed 2022-11-02 | $98.24M derived: sum of 2 quarters · filed 2022-11-02 | $140.12M 10-Q · filed 2022-11-02 | $176.61M derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2021-06-30 | $45.00M 10-Q · filed 2022-08-04 | $86.88M 10-Q · filed 2022-08-04 | $123.37M derived: sum of 3 quarters · filed 2023-03-16 | $163.42M derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2021-03-31 | $41.88M 10-Q · filed 2022-05-10 | $168.93M 10-Q · filed 2021-05-05 | $78.37M derived: sum of 2 quarters · filed 2023-03-16 | $118.43M derived: sum of 3 quarters · filed 2023-03-16 | $148.42M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2020-12-31 | $36.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $76.55M derived: sum of 2 quarters · filed 2023-03-16 | $106.54M derived: sum of 3 quarters · filed 2023-03-16 | $132.94M 10-K · filed 2023-03-16 | ||
| 2020-09-30 | $40.06M 10-Q · filed 2021-11-08 | $70.05M derived: sum of 2 quarters · filed 2021-11-08 | $96.45M 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | $29.99M 10-Q · filed 2021-08-04 | $56.40M 10-Q · filed 2021-08-04 | ||||
| 2020-03-31 | $27.32M 10-Q · filed 2021-05-05 | |||||
| 2019-12-31 | $99.59M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |